[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-carcinoma":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100592628","the-vanguard-study-testing-a-new-way-to-screen-for-cancer-100592628",false,"NCT06995898","The Vanguard Study: Testing a New Way to Screen for Cancer","Inclusion Criteria:\n\n* Ages 45-75 years old\n* Agree to provide blood samples for possible MCD testing at enrollment and at 1 year following enrollment\n* Agree to allow collection of information from their medical records for study-related purposes\n* Understand and be able to complete informed consent and participant questionnaires in English, Spanish, or Arabic\n\n  * Note: Eligibility for Spanish and Arabic languages are at the Hub's discretion\n\nExclusion Criteria:\n\n* Solid malignant tumor or blood cancer diagnosis, with or without treatment, within the last 5 years\n\n  * Note: Persons with a history of in situ cancers (e.g., ductal carcinoma in situ of the breast, cervical cancer in situ, atypical melanocytic hyperplasia or melanoma in situ) or nonmelanoma skin cancer are eligible\n* Ongoing cancer diagnostic work-up\n* Ongoing participation in another study of an investigational cancer screening test or technology\n* Currently breastfeeding or pregnant, or planning to become pregnant in the next year",true,"ALL","45 Years","75 Years",{"count":20,"type":21},24000,"ESTIMATED","INTERVENTIONAL",[24],"NA","The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).",[27,28,29,30,31,32,33,34,35,36,37],"Bladder Carcinoma","Breast Carcinoma","Colorectal Carcinoma","Esophageal Carcinoma","Gastric Carcinoma","Liver Carcinoma","Lung Carcinoma","Malignant Solid Neoplasm","Ovarian Carcinoma","Pancreatic Carcinoma","Prostate Carcinoma","RECRUITING","2026-06-30",{"date":41,"type":42},"2026-07-01","ACTUAL",{"date":44,"type":42},"2025-06-18",{"date":46,"type":21},"2029-06-30",{"name":48,"class":49},"National Cancer Institute (NCI)","NIH",38,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":15,"sex":16,"minAge":58,"maxAge":18,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":71,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":98},"100571211","the-ccaned-cipher-study-early-cancer-detection-and-treatment-response-monitoring-using-ai-based-platelet-and-immune-cell-transcriptomic-profiling-100571211","NCT06717295","The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling","CCANED-CIPHER","Phase 1 (Common Cancer Early Detection - CCANED)\n\nInclusion Criteria:\n\n* Age: Adults aged 40 years or older.\n* Confirmed diagnosis of one of the following common cancers: Non-Small Cell Lung Cancer (NSCLC), Glioblastoma Multiforme (GBM), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Breast Cancer, Prostate Cancer, Ovarian Cancer, Pancreatic Cancer.\n\nExclusion Criteria:\n\n* Currently pregnant.\n* Presence of any active infectious diseases.\n* Use of anticoagulant or antiplatelet drugs within the past 2 weeks.\n* Any medical or psychological conditions that may affect the participant's ability to comply with study procedures.\n\nPhase 2 ( Cancer Immuno-Profiling of Hematologic and Extracellular RNA - CIPHER)\n\nInclusion Criteria:\n\n* Adults aged 40 years or older.\n* Confirmed diagnosis of: Hepatocellular Carcinoma (HCC), Non-Small Cell Lung Cancer (NSCLC)\n* Willingness to provide blood samples at the specified intervals (baseline, 6 weeks, and 6 months post-therapy initiation).\n\nExclusion Criteria:\n\n* Presence of another malignancy unless it has been in remission for at least 5 years.\n* Significant uncontrolled co-morbid conditions that may interfere with study participation or outcomes.","40 Years",{"count":60,"type":21},6000,"OBSERVATIONAL","The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. By analysing blood samples using artificial intelligence, the study seeks to create a safe, non-invasive method to enhance cancer diagnosis and monitor treatment responses over time.",[64,65,66,67,68,69,70,32],"Brest Cancer","Lung Cancer (NSCLC)","Pancreatic Cancer, Adult","Prostate Cancers","Ovarian Cancer","Colorectal Cancer","Glioblastoma (GBM)",[72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87],"cancer screening","Liquid Biopsy","AI-based Diagnostics","Early Cancer Detection","Circulating Tumor DNA (ctDNA)","RNA Profiling","Biomarker","Precision Medicine","Oncology","Health Data Analysis","Platelets","treatment response","RNA","CircRNA","Splicing","Cancer","2025-12-29",{"date":90,"type":42},"2026-01-02",{"date":92,"type":42},"2025-12-20",{"date":94,"type":21},"2028-08-01",{"name":96,"class":97},"Javier Toledo","INDUSTRY",4]